FDA accepts Rezzayo supplemental NDA for priority review
CorMedix announced FDA acceptance of its supplemental new drug application for Rezzayo (rezafungin) for priority review for prophylaxis of invasive fungal diseases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.